To Present at Noble Financial 'Double-O-Seven' Small Cap Conference/Microcap Symposium on August 21 and Roth Capital's 2007 New York
Conference on September 5
NEWARK, Del., Aug. 15 /PRNewswire-FirstCall/ -- Strategic Diagnostics Inc. (Nasdaq: SDIX) -- a leading provider of biotechnology-based detection solutions for a broad range of food, water, agricultural, environmental and life science applications, announced today that its President and Chief Executive Officer, Matthew Knight, will present at two investor conferences during the next three weeks.
Mr. Knight will present at Noble Research's "Two-Double-O-Seven" Small Cap Conference/Microcap Symposium at the Charleston Place Hotel in the heart of Charleston South Carolina's historic district. The Company will present at 8:30 a.m. on August 21 in the Goldfinger Room with a live webcast available at the Conference's website, http://www.two-007.net, for approximately 30 days following the conclusion of the presentation. The Company will have a breakout session immediately following the formal presentation in the Diamonds are Forever room. Company management will be available for one-on-one meetings throughout the day, which may be arranged by emailing Noble Research at firstname.lastname@example.org.
On September 5, Mr. Knight will present at Roth Capital Partner's Roth 2007 New York Conference at the Westin Hotel in Manhattan. Mr. Knight's presentation is scheduled for 4:30 p.m. in the Majestic II (Track 1) room. A webcast of the presentation may be accessed at http://www.wsw.com/webcast/roth13/sdix/ for approximately 30 days following the conclusion of the presentation. Following the presentation, Mr. Knight will attend a breakout session. One-on-one meetings may be scheduled through Roth Capital Partners by calling (212) 201-2700.
Each presentation is designed to provide analysts, institutional brokers and portfolio managers with an overview of the Company's expertise in the production of antibodies, used both in diagnostic tests and provided to the proteomics, pharmaceutical, diagnostics and biomedical research industries to enable rapid discovery and commercialization of products. Strategic Diagnostics is a leader in the food pathogen industry, providing comprehensive, accurate, and easy-to-use tests including the recently introduced RapidChek(R) SELECT(TM) Salmonella product. The Company is also an emerging leader in producing monoclonal and polyclonal antibodies for the pharmaceutical and research industries. The Company's patent-pending technology also addresses renewable energy opportunities and can be used to increase efficiency in the production of ethanol. Management will discuss the recurring revenue component of the Company's business model, revenue potential from new product and services, and the Company's strategy for sustainable growth.
About The Noble Financial/Two-Double-O-Seven Small Cap Conference/Microcap Symposium
Noble Financial supports emerging growth companies through strategic advice, investment banking, market-making, sales & trading, comprehensive equity research, and the development of institutional support. Noble's equity conferences allow for a unique blend of professional and personal interaction among a diverse cross-section of executives. The goal is to deliver outstanding business organization, world-class accommodation and meeting facilities, and memorable social events.
About the Roth Capital Partners and the 2007 New York Conference
Roth is one of the last remaining independent full-service investment banks dedicated to the small and micro-cap market. The firm is privately owned with current principals being majority owners. The core management team has been consistent for many years. Since the inception of the firm in 1984, Roth has been a leader and innovator in the small and micro cap markets. Roth's exclusive focus has been, is, and will continue to offer a full spectrum of investment banking services, including raising capital, research coverage, trading and market making, merger and acquisition advisory services, and investor conferences. Roth's award-winning research is the foundation of its firm and key to its understanding of the micro- and small-cap sector. This research, when combined with a seasoned institutional sales team and its highly visible investor conferences, creates an unparalleled institutional sponsorship platform for growth companies. Roth has raised more than $10 billion for small and micro cap public companies and completed over 135 merger, acquisition and advisory assignments. Since year 2000, Roth has been a leading placement agent for the number of PIPE transactions, raising over $2 billion for its clients. Roth received top 20 IPO aftermarket performance rankings for six consecutive years from 1994 to 1999. The 5th Annual New York Conference is a two-day event with more than 230 presenting companies and is attended by over 1,200 buy side investors. The 2006 conference had more than 2,000 one-on-one meetings.
About Strategic Diagnostics Inc.
Strategic Diagnostics Inc. develops, manufactures and markets biotechnology-based detection solutions to a diverse customer base, across multiple industrial and human health markets. By applying its core competency of creating custom antibodies to assay development, the Company produces unique, sophisticated diagnostic testing and reagent systems that are responsive to customer diagnostic and information needs. Customers benefit with quantifiable "return on investment" by reducing time, labor, and/or material costs. All this is accomplished while increasing accuracy, reliability and actionability of essential test results. The Company is focused on sustaining this competitive advantage by leveraging its expertise in immunology, proteomics, bio-luminescence and other bio-reactive technologies to continue its successful customer-focused research and development efforts. Recent innovations in high throughput production of antibodies from genetic antigens will complement the Company's established leadership in commercial and custom antibody production for the Research, Human/Animal Diagnostics, and Pharmaceutical industries, and position the Company for broader participation in proteomics research and discovery.
This news release contains forward-looking statements reflecting SDI's current expectations. When used in this press release, the words "anticipate", "could", "enable", "estimate", "intend", "expect", "believe", "potential", "will", "should", "project", "plan" and similar expressions as they relate to SDI are intended to identify said forward-looking statements. Investors are cautioned that all forward-looking statements involve risks and uncertainties, which may cause actual results to differ from those anticipated by SDI at this time. Such risks and uncertainties include, without limitation, changes in demand for products, delays in product development, delays in market acceptance of new products, retention of customers and employees, adequate supply of raw materials, inability to obtain or delays in obtaining fourth party, including AOAC, or required government approvals, the ability to meet increased market demand, competition, protection of intellectual property, non-infringement of intellectual property, seasonality, and other factors more fully described in SDI's public filings with the U.S. Securities and Exchange Commission.
Chief Financial Officer
Brett Maas (email@example.com)
|SOURCE Strategic Diagnostics Inc.|
Copyright©2007 PR Newswire.